Mature osteoclast

Mature osteoclasts are large, multinucleated cells derived from the monocyte-macrophage lineage that are specialized for the degradation of mineralized bone matrix (StatPearls, NBK537131). They play a critical role in bone remodeling and calcium homeostasis by secreting protons and proteolytic enzymes, such as Cathepsin K, into a sealed resorptive pit known as Howship's lacuna (PubMed, 22431267). Overactivity of mature osteoclasts is a hallmark of metabolic bone diseases like osteoporosis and Paget's disease, as well as bone destruction associated with cancer metastases (NIH, Osteoporosis Overview). Therapeutic strategies often focus on reducing osteoclast number or activity through the use of bisphosphonates, which promote osteoclast apoptosis, or biologics like denosumab that inhibit the RANKL-mediated signaling required for their survival and function (FDA, Prolia Label). While effective at increasing bone mineral density, long-term suppression of mature osteoclasts can lead to complications such as atypical fractures or osteonecrosis of the jaw due to severely reduced bone turnover (ASBMR, 10.1002/jbmr.2730).

Other names

OsteoclastBone-resorbing cellMultinucleated giant cell of bone

Therapeutic agents target mature osteoclasts by inhibiting their formation, activity, or survival. Bisphosphonates bind to hydroxyapatite and are internalized by osteoclasts, where they inhibit the mevalonate pathway or induce apoptosis (PubMed, 17472468). Denosumab binds to RANKL, preventing it from activating the RANK receptor on osteoclasts, thereby inhibiting their maturation and function (PubMed, 20553361). Cathepsin K inhibitors directly block the enzyme responsible for degrading the organic bone matrix (PubMed, 27163160).